N

NeuBase Therapeutics Inc
F:O7PA

Watchlist Manager
NeuBase Therapeutics Inc
F:O7PA
Watchlist
Price: 0.159 EUR -3.64%
Market Cap: 107.5m EUR

NeuBase Therapeutics Inc
Depreciation & Amortization

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

NeuBase Therapeutics Inc
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
N
NeuBase Therapeutics Inc
F:O7PA
Depreciation & Amortization
$710k
CAGR 3-Years
36%
CAGR 5-Years
-9%
CAGR 10-Years
23%
Abbvie Inc
NYSE:ABBV
Depreciation & Amortization
$8.3B
CAGR 3-Years
0%
CAGR 5-Years
11%
CAGR 10-Years
27%
Gilead Sciences Inc
NASDAQ:GILD
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Depreciation & Amortization
$200.6m
CAGR 3-Years
12%
CAGR 5-Years
14%
CAGR 10-Years
12%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Depreciation & Amortization
$525.1m
CAGR 3-Years
18%
CAGR 5-Years
18%
CAGR 10-Years
23%
No Stocks Found

NeuBase Therapeutics Inc
Glance View

Market Cap
107.5m EUR
Industry
Biotechnology

NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 33 full-time employees. The firm is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA) and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type one disease mRNA.

O7PA Intrinsic Value
Not Available

See Also

What is NeuBase Therapeutics Inc's Depreciation & Amortization?
Depreciation & Amortization
710k USD

Based on the financial report for Sep 30, 2023, NeuBase Therapeutics Inc's Depreciation & Amortization amounts to 710k USD.

What is NeuBase Therapeutics Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
23%

Over the last year, the Depreciation & Amortization growth was -8%. The average annual Depreciation & Amortization growth rates for NeuBase Therapeutics Inc have been 36% over the past three years , -9% over the past five years , and 23% over the past ten years .

Back to Top